Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Hoechst Marion Roussel reports new antidepressants

Sep. 20, 1996

Fluphenazine ANDA approval

Sep. 20, 1996

New dopamine D4 receptor antagonists from Taisho and Nihon Nohyaku

Sep. 20, 1996

Anxiolytic/antidepressant approved in Japan

Sep. 20, 1996

Mitochondrial benzodiazepine receptor (MBR) ligands as potential anxiolytics

Sep. 20, 1996

Glaxo Wellcome identifies potential anxiolytic agents

Sep. 20, 1996

New CNS agents from American Cyanamid

Sep. 20, 1996

American Home Products investigates 5-HT1A antagonists for anxiety

Sep. 20, 1996

The effects of clonidine on sleep

Sep. 20, 1996

Combination analgesic progresses through clinical trials

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...